The Claim
In individuals with systemic inflammation, pancreatic structural disease, and clonal hematopoiesis of indeterminate potential (CHIP), hemoglobin A1c (HbA1c) levels may remain within the normal range despite persistent hyperglycemia detected by continuous glucose monitoring (CGM) and oral glucose tolerance testing (OGTT), due to reduced red blood cell lifespan caused by inflammation, which limits the time available for glucose to glycate hemoglobin.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Some people with chronic inflammation and certain blood and pancreas conditions might have normal blood sugar readings on standard A1c tests, even though their actual blood sugar is high — because inflammation makes red blood cells die faster, so there's less time for sugar to stick to them.
See the scientific wording
In individuals with systemic inflammation, pancreatic structural disease, and clonal hematopoiesis of indeterminate potential (CHIP), hemoglobin A1c (HbA1c) may remain within normal limits despite persistent hyperglycemia detected by continuous glucose monitoring (CGM) and oral glucose tolerance testing (OGTT), due to inflammation-associated reductions in red blood cell lifespan that limit glycation time.
What the research says
1 studyThe patient had conditions that should have caused high blood sugar, and tests confirmed it—but her HbA1c blood test looked normal. The doctors think inflammation and blood changes shortened her red blood cell life, so there wasn’t enough time for sugar to stick to them, making HbA1c misleading.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.